Vicore Pharma Holding AB

Report 52-week topline results from the Phase 2b ASPIRE trial of buloxibutid

Deadline not yet reached (246 days left)

Announced: 22 Oct 2026
Due: 30 Jun 2027

Deadline
Met
Late
Not met
Today

What the company said

“ASPIRE continues as planned and remains on track to report 52-week topline results in mid-2027.”

SourceVicore Pharma Holding AB Form 6-K press release, 2026-10-22
Archived copyWayback Machine snapshot
FilingSEC filing index
Deadline as statedin mid-2027
Deadline used30 Jun 2027, the last day of the stated period
TypeProject
Permanent referenceKI-C-2026-VCRE-024179
Cite as https://keptindex.org/c/KI-C-2026-VCRE-024179/ — this address never changes.

What we found

The deadline has not passed yet, so there is nothing to check. We look for evidence starting 30 days after 30 Jun 2027.

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type: Clinical readout
Indicative materiality: Medium rules
Action: Report
Deliverable: 52-week topline results from Phase 2b ASPIRE trial
Language: Aspirational (“aims”, “intends”)
In the company’s control: Medium
Specificity: Medium

Tell me what happens

This deadline has not been settled yet. We check 30 days after it passes. Get an email when we record the outcome.

Alert me when this resolves

How this entry was checked

Commitment recordedThe company's words were matched word for word against the filing.
OutcomeNot yet assessed. Nothing is judged before the deadline.

Are you Vicore Pharma Holding AB? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.

Report an error in this entry Reference: KI-C-2026-VCRE-024179 · Corrections policy